基于机器学习从司库奇尤单抗治疗银屑病关节炎临床开发项目中识别具有临床相关性的患者聚类
研究汇总四项3期研究(FUTURE 2-5)中1894例接受司库奇尤单抗治疗的银屑病关节炎患者的基线数据,用有限混合模型识别出7个基于关节、附着点和皮肤表现的临床聚类,并用机器学习比较300 mg与150 mg在各聚类中的纵向应答,发现不同聚类对司库奇尤单抗的应答轨迹存在差异。
要点
- 基于基线关节、附着点和皮肤表现,银屑病关节炎患者可被机器学习分为7个临床聚类。
- 聚类1为极高度肿胀和压痛关节负荷,聚类2为高度压痛关节负荷,聚类3为高度足部关节和指趾炎负荷。
- 聚类4至7关节负荷低但甲和皮肤受累程度不一,聚类7为所有领域疾病活动度均轻度。
核心结论
- 机器学习识别的银屑病关节炎聚类呈现不同的应答轨迹,提示其可能有助于预测对患者结局的精准影响。
研究设计与样本
- 汇总四项3期研究(FUTURE 2-5)中1894例接受司库奇尤单抗治疗的银屑病关节炎患者的基线数据。
- 采用有限混合模型方法生成临床聚类,并通过机器学习技术比较司库奇尤单抗300 mg与150 mg在各聚类和临床指标中至第52周的平均纵向应答。
主要发现
- 共识别出7个不同的患者聚类。
- 聚类1(极高度肿胀/压痛;n=187)以关节压痛和肿胀的极高度多关节负荷为特征。
- 聚类2(高度压痛;n=251)以压痛关节的高度多关节负荷为特征,聚类3(高度足部-指趾炎;n=175)以足部关节和指趾炎的高度负荷为特征。
- 聚类4(低度甲-皮肤;n=209)、聚类5(低度皮肤;n=283)、聚类6(低度甲;n=294)和聚类7(低度;n=495)关节负荷低但甲和皮肤受累程度不一,聚类7以所有领域疾病活动度均轻度为特征。
- 聚类2的附着点炎、聚类4的附着点炎和银屑病面积与严重程度指数(PASI)、聚类6的PASI,司库奇尤单抗300 mg较150 mg显示更大的纵向应答改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Identify distinct clusters of psoriatic arthritis (PsA) patients based on their baseline articular, entheseal and cutaneous disease manifestations and explore their clinical and therapeutic value. METHODS: Pooled baseline data in PsA patients (n=1894) treated with secukinumab across four phase 3 studies (FUTURE 2-5) were analysed to determine phenotypes based on clusters of clinical indicators. Finite mixture models methodology was applied to generate clinical clusters and mean longitudinal responses were compared between secukinumab doses (300 vs 150 mg) across identified clusters and clinical indicators through week 52 using machine learning (ML) techniques. RESULTS: Seven distinct patient clusters were identified. Cluster 1 (very-high (VH) - SWO/TEN (swollen/tender); n=187) was characterised by VH polyarticular burden for both tenderness and swelling of joints, while cluster 2 (H (high) - TEN; n=251) was marked by high polyarticular burden in tender joints and cluster 3 (H - Feet - Dactylitis; n=175) by high burden in joints of feet and dactylitis. For cluster 4 (L (Low) - Nails - Skin; n=209), cluster 5 (L - skin; n=283), cluster 6 (L - Nails; n=294) and cluster 7 (L; n=495) articular burden was low but nail and skin involvement was variable, with cluster 7 marked by mild disease activity across all domains. Greater improvements in the longitudinal responses for enthesitis in cluster 2, enthesitis and Psoriasis Area and Severity Index (PASI) in cluster 4 and PASI in cluster 6 were shown for secukinumab 300 mg compared with 150 mg. CONCLUSIONS: PsA clusters identified by ML follow variable response trajectories indicating their potential to predict precise impact on patients' outcomes. TRIAL REGISTRATION NUMBERS: NCT01752634, NCT01989468, NCT02294227, NCT02404350.
引用
- Pournara E, Kormaksson M, Nash P, et al. Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD Open. 2021. PMID: 34795065. doi:10.1136/rmdopen-2021-001845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。